Affiliation:
1. Center for Outcomes Research and Evaluation Yale New Haven Hospital New Haven CT
2. Section of Cardiovascular Medicine, Department of Internal Medicine Yale School of Medicine New Haven CT
3. Department of Health Policy and Management Yale School of Public Health New Haven CT
Abstract
Background
Semaglutide holds the promise for weight loss and risk reduction. Less is known about racial and ethnic disparities in financial barriers among the semaglutide‐eligible population.
Methods and Results
We conducted a cross‐sectional analysis of adults aged 18 years or older using data from the National Health and Nutrition Examination Survey 2015 to 2020. We analyzed adults eligible for semaglutide based on Food and Drug Administration labeling and assessed financial barriers and social determinants of health among the eligible population overall and by race and ethnicity. A total of 13 711 adults were included in the final analysis. In 2015 to 2020, 51.1% (48.3%–53.2%) of US adults (≈112.5 million) met the Food and Drug Administration eligibility criteria for semaglutide. The percentage of adults eligible for semaglutide was highest among Black adults (56.6% [54.2%–59.1%]), followed by Hispanic adults (55.0% [52.8%–57.3%]). Among adults eligible for semaglutide, 11.9% (10.1%–13.6%) were uninsured, 13.3% (12.1%–14.5%) lacked a usual source of care, 33.6% (30.2%–36.9%) had low family income, and 38.9% (36.5%–41.3%) lacked higher education. Compared with White individuals, significantly larger proportions of Black and Hispanic individuals were uninsured, lacked a usual source of care, had low family income, or lacked higher education (
P
<0.001 for all).
Conclusions
Many Americans who were eligible for semaglutide were likely to be unable to afford the medication. Among the eligible population, a larger proportion of Black and Hispanic adults had financial barriers than other subgroups.
Publisher
Ovid Technologies (Wolters Kluwer Health)
Subject
Cardiology and Cardiovascular Medicine
Reference15 articles.
1. US Food and Drug Administration
. FDA approves new drug treatment for chronic weight management first since 2014. Available at: https://www.fda.gov/news‐events/press‐announcements/fda‐approves‐new‐drug‐treatment‐chronic‐weight‐management‐first‐2014. Accessed October 17 2021.
2. Once-Weekly Semaglutide in Adults with Overweight or Obesity
3. Bariatric Surgery versus Intensive Medical Therapy for Diabetes — 3-Year Outcomes
4. Kolata G. The doctor prescribed an obesity drug. Her Insurer Called It ‘Vanity.’ Available at: https://www.nytimes.com/2022/05/31/health/obesity‐drugs‐insurance.html. Accessed June 1 2022.
5. Trends in Differences in Health Status and Health Care Access and Affordability by Race and Ethnicity in the United States, 1999-2018
Cited by
10 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献